Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer

被引：7

作者：

Ziyeh, Sharvina ^{[1
,2
]}

Wong, Lauren ^{[2
]}

Basho, Reva K. ^{[2
,3
]}

机构：

[1] UCLA, Olive View Med Ctr, Los Angeles, CA USA

[2] Cedars Sinai Med Ctr, Los Angeles, CA USA

[3] Lawrence J Ellison Inst Transformat Med, Los Angeles, CA 90064 USA

来源：

CURRENT ONCOLOGY REPORTS | 2023年 / 25卷 / 07期

关键词：

Hormone receptor-positive breast cancer; HER2 negative breast cancer; Endocrine therapy; CDK4/6; inhibition; PI3K inhibition; AKT inhibition; PIK3CA mutation; SERDs; SERMs; PROTACs; SERCAs; CERANs; SARMs; DOUBLE-BLIND; AROMATASE INHIBITOR; PLUS FULVESTRANT; MULTICENTER; PALBOCICLIB; WOMEN; ABEMACICLIB; PROGRESSION; EXPRESSION; MUTATIONS;

D O I：

10.1007/s11912-023-01393-6

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose of Review To provide an overview of the current management of hormone receptor-positive (HR +) advanced breast cancer as well as highlight ongoing clinical investigation and novel therapies in development. Recent Findings CDK4/6 inhibition plus endocrine therapy is standard front-line therapy for HR + advanced breast cancer. Continuation of CDK4/6 inhibitors in combination with alternative endocrine therapy has been evaluated in the second-line setting. Alternatively, endocrine therapy in combination with PI3K/AKT pathway targeting agents has been studied, particularly in patients with PI3K pathway alterations. The oral SERD elacestrant has also been evaluated in patients with ESR1 mutation. Many novel endocrine agents and targeted agents are in development. An improved understanding of combination therapies and sequencing of therapies is needed to optimize the treatment paradigm. Biomarker development is needed to guide treatment decisions. Summary Advances in the treatment of HR + breast cancer have resulted in improved patient outcomes in recent years. Continued development efforts with identification of biomarkers to better understand response and resistance to therapy are needed.

引用

页码：689 / 698

页数：10

共 50 条

[1] Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Sharvina Ziyeh
Lauren Wong
Reva K. Basho
[J]. Current Oncology Reports, 2023, 25 : 689 - 698
[2] Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer
Tevaarwerk, Amye J.
Wisinski, Kari B.
O'Regan, Ruth M.
[J]. JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (11) : 1148 - +
[3] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer
Reinert, Tomas
Barrios, Carlos H.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1959 - +
[4] Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways
Johnston, Stephen R. D.
[J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (10)
[5] The Optimal Duration of Endocrine Therapy in Hormone Receptor-Positive Breast Cancer
Sledge, George W., Jr.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (06) : 383 - 404
[6] Neoadjuvant therapy for hormone receptor-positive breast cancer: challenges and advances
Metzger, O.
[J]. CANCER RESEARCH, 2020, 80 (04)
[7] Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply
Ellis, Matthew J.
Robertson, John F. R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (16) : 1960 - +
[8] Changing Concepts of Hormone Receptor-Positive Advanced Breast Cancer Therapy
Chlebowski, Rowan T.
[J]. CLINICAL BREAST CANCER, 2013, 13 (03) : 159 - 166
[9] Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
Bian Li
Xu Feng-Rui
Jiang Ze-Fei
[J]. 中华医学杂志(英文版), 2020, 133 (19) : 2338 - 2345
[10] Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer
Bian, Li
Xu, Feng-Rui
Jiang, Ze-Fei
[J]. CHINESE MEDICAL JOURNAL, 2020, 133 (19) : 2338 - 2345

← 1 2 3 4 5 →